NCT00676143 · Phase 3 · TERMINATED
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
This trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. Researchers measured safety and whether it affected thinking and daily function over about 1.5 years. It was a Phase 3 trial, a large late-stage test of whether a drug works and is safe, not an approved treatment.
You may qualify if
- Diagnosis of probable AD, with MMSE score of 16-26, and brain MRI consistent with the diagnosis of AD
- Concurrent use of cholinesterase inhibitor or memantine allowed, if stable.
- Caregiver will participate and be able to attend clinic visits with patient.
You're excluded if
- Significant neurological disease other than AD, or a major psychiatric disorder
- Contraindication to undergo brain MRI (e.g., pacemaker, CSF shunt, or foreign metal objects in the body)
- Woman of childbearing potential
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2016-06-10